Atrial fibrillation has always been frustratingly resistant to a cure. Even among the so-called easiest groups of patients, those with paroxysmal atrial fibrillation (which is intermittent and terminates on its own), conventional ablation procedures using radiofrequency or some other energy modality to scar the heart and isolate the instigating electrical impulses (or triggers) provide long-term freedom from AF only 50% of the time. The search for better efficacy is compelling because patients that suffer from atrial fibrillation have a five to seven-fold increased risk for stroke.
While much of the cardiology industry has tried to improve the results by incrementally improving the therapies, Topera Medical Inc. challenges the assumptions upon which therapy has been based....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?